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Tacrine is an acetylcholinesterase (AChE) inhibitor used as a cognitive enhancer in the 
treatment of Alzheimer’s disease (AD). However, its low therapeutic efficiency and a high 
incidence of side effects have limited its clinical use. In this study, the molecular 
mechanisms underlying the impact on brain activity of tacrine and two novel tacrine 
analogues (T1, T2) were approached by focusing on three aspects: (i) their effects on brain 
cholinesterase activity; (ii) perturbations on electron transport chain enzymes activities of 
non-synaptic brain mitochondria; and (iii) the role of mitochondrial lipidome changes 
induced by these compounds on mitochondrial bioenergetics. Brain effects were evaluated 
18 h after the administration of a single dose (75.6 micromoles/kg) of tacrine or tacrine 
analogues. The three compounds promoted a significant reduction in brain AChE and 
butyrylcholinesterase (BuChE) activities. Additionally, tacrine was shown to be more 
efficient in brain AChE inhibition than T2 tacrine analogue and less active than T1 tacrine 
analogue, whereas BuChE inhibition followed the order: T1 > T2 > tacrine. The studies 
using non-synaptic brain mitochondria show that all the compounds studied disturbed brain 
mitochondrial bioenergetics mainly via the inhibition of complex I activity. Furthermore, 
the activity of complex IV is also affected by tacrine and T1 treatments while FoF1-
ATPase is only affected by tacrine. Therefore, the compounds’ toxicity as regards brain 
mitochondria, which follows the order: tacrine >> T1 > T2, does not correlate with their 
ability to inhibit brain cholinesterase enzymes. Lipidomics approaches show that 
phosphatidylethanolamine (PE) is the most abundant phospholipids (PL) class in non-
synaptic brain mitochondria and cardiolipin (CL) present the greatest diversity of 
molecular species. Tacrine induced significant perturbations in the mitochondrial PL 
profile, which were detected by means of changes in the relative abundance of 
phosphatidylcholine (PC), PE, phosphatidylinositol (PI) and CL and by the presence of 
oxidized phosphatidylserines. Additionally, in both the T1 and T2 groups, the lipid content 
and molecular composition of brain mitochondria PL are perturbed to a lesser extent than 
in the tacrine group. Abnormalities in CL content and the amount of oxidized 
phosphatidylserines were associated with significant reductions in mitochondrial enzymes 
activities, mainly complex I. These results indicate that tacrine and its analogues impair 
mitochondrial function and bioenergetics, thus compromising the activity of brain cells. 
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